{
  "id": 16879467,
  "title": "Rakovina Therapeutics and Celvion Therapeutics Complete AI Analysis Identifying Priority Cancer Indications for Brain-Penetrant ATR Inhibitor Program",
  "url": "https://urgent.news/2026/10/28/rakovina-therapeutics-and-celvion-therapeutics-complete-ai-analysis",
  "topic": "ai",
  "section": "AI",
  "published": "2026-10-28T09:30:55.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/rakovina-therapeutics-and-celvion-therapeutics-complete-ai-analysis-identifying-priority-cancer-indications-for-brain-penetrant-atr-inhibitor-program"
  },
  "original_language": "en",
  "account": null,
  "summary": "EMphora™ platform integrates clinical evidence and predictive modelling to help identify promising cancer patient populations and guide the next phase of research VANCOUVER, British Columbia, Oct. 28, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, and…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}